Introduction: This study aimed to investigate whether epigallocatechin-3-gallate (EGCG) shows antioxidant activity against angiotensin II (Ang II)-induced human umbilical vein endothelial cell (HUVEC) apoptosis. Materials and Methods: The viability of HUVECs was revealed by MTT and LDH assay. The cell apoptosis was detected by FITC-PI assay. A fluorescent probe assay was used to measure the reactive oxygen species (ROS) generation in HUVECs. Mitochondrial permeability transition pore (MPTP) opening, mitochondrial membrane potential, and caspase-3, -4, -8, -9 activities were also measured. Results: We found that Ang II treatment increased the generation of ROS, enhanced MPTP opening and cytochrome c release, activated caspase-3/9, and consequently induced HUVEC apoptosis. EGCG treatment-suppressed Ang II induces the oxidative stress of HUVECs and mitochondria-related cell apoptosis. We also showed that the antioxidant activity pathway, including cytochrome c release, MPTP opening, and caspase-3/9 activation, is a key endogenous defensive system in HUVECs, provoking Ang II exposure. Our study revealed that increased expression of Nrf2 by EGCG could partially repress Ang II-induced injury effects. Conclusions: All of our findings indicated that EGCG treatment provides a protective effect for Ang II-induced HUVEC apoptosis by decreasing oxidative stress and ameliorating mitochondrial injury.

Keywords:
Epigallocatechin-3-gallate, Angiotensin II, Human umbilical vein endothelial cells, Oxidative stress, Nrf2
1.
Ren H, Mu J, Ma J, et al: Selenium inhibits homocysteine-induced endothelial dysfunction and apoptosis via activation of AKT. Cell Physiol Biochem 2016;38:871-882.
2.
Wang F, Pu C, Zhou P, et al: Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating Nrf2. Cell Physiol Biochem 2015;36:315-324.
3.
Chen F, Li X, Aquadro E, et al: Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension. Free Radic Biol Med 2016;99:167-178. 2016/10/23.
4.
Kruger R, Mothae M, Smith W: Yia 03-07 reactive oxygen species adversely relates to early vascular changes and arterial stiffness in black normotensive smokers: the African-Predict Study. J Hypertens 2016;34(suppl 1):e205-e206.
5.
Gonzalez GE, Rhaleb NE, D'Ambrosio MA, et al: Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2016;311:H1287-H1296.
6.
Rosenbaugh EG, Savalia KK, Manickam DS, et al: Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 2013;304:R917-R928.
7.
Montezano AC, Burger D, Paravicini TM, et al: Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 2010;106:1363-1373.
8.
El Bekay R, Alvarez M, Monteseirin J, et al: Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 2003;102:662-671.
9.
Miura S, Saku K: Recent progress in the treatment of cardiovascular disease using olmesartan. Clin Exp Hypertens 2014;36:441-446.
10.
Burrell L: Sy 12-1 renin angiotensin pathway beyond ace and angiotensin II receptors: how it relates to the pathophysiology of hypertension. J Hypertens 2016;34(suppl 1):e367.
11.
Feng W, Zhang K, Liu Y, et al: Apocynin attenuates angiotensin II-induced vascular smooth muscle cells osteogenic switching via suppressing extracellular signal-regulated kinase 1/2. Oncotarget 2016;7:83588-83600.
12.
Shi L, Wu L, Chen Z, et al: MiR-141 activates Nrf2-dependent antioxidant pathway via down-regulating the expression of Keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell Physiol Biochem 2015;35:2333-2348.
13.
Liu W, Wang B, Wang T, et al: Ursodeoxycholic acid attenuates acute aortic dissection formation in angiotensin II-infused apolipoprotein E-deficient mice associated with reduced ROS and increased Nrf2 levels. Cell Physiol Biochem 2016;38:1391-1405.
14.
Gong W, Li J, Chen Z, et al: Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating CKIP-1 to resist HG-induced up-regulation of FN and ICAM-1 in GMCs and diabetic mice kidneys. Free Radic Biol Med 2017;106:393-405.
15.
Yagishita Y, Uruno A, Fukutomi T, et al: Nrf2 improves leptin and insulin resistance provoked by hypothalamic oxidative stress. Cell Rep 2017;18:2030-2044.
16.
Peng S, Hou Y, Yao J, et al: Activation of Nrf2-driven antioxidant enzymes by cardamonin confers neuroprotection of PC12 cells against oxidative damage. Food Funct 2017;8:997-1007.
17.
Rasheed NO, Ahmed LA, Abdallah DM, et al: Nephro-toxic effects of intraperitoneally injected EGCG in diabetic mice: involvement of oxidative stress, inflammation and apoptosis. Sci Rep 2017;7:40617.
18.
Zhang J, Lei Z, Huang Z, et al: Epigallocatechin-3-gallate (EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget 2016;7:79557-79571.
19.
Oyama JI, Shiraki A, Nishikido T, et al: EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice. J Cardiol 2017;69:417-427.
20.
Li M, Li JJ, Gu QH, et al: EGCG induces lung cancer A549 cell apoptosis by regulating Ku70 acetylation. Oncol Rep 2016;35:2339-2347.
21.
Fang CY, Wu CC, Hsu HY, et al: EGCG inhibits proliferation, invasiveness and tumor growth by up-regulation of adhesion molecules, suppression of gelatinases activity, and induction of apoptosis in nasopharyngeal carcinoma cells. Int J Mol Sci 2015;16:2530-2558.
22.
Adikesavan G, Vinayagam MM, Abdulrahman LA, et al: (-)-Epigallocatechin-gallate (EGCG) stabilize the mitochondrial enzymes and inhibits the apoptosis in cigarette smoke-induced myocardial dysfunction in rats. Mol Biol Rep 2013;40:6533-6545.
23.
Ye R, Yang Q, Kong X, et al: Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem Int 2011;58:391-398.
24.
Li P, Guo X, Lei P, et al: PI3K/Akt/uncoupling protein 2 signaling pathway may be involved in cell senescence and apoptosis induced by angiotensin II in human vascular endothelial cells. Mol Biol Rep 2014;41:6931-6937.
25.
Hieronimus B, Pfohl J, Busch C, et al: Expression and characterization of membrane-type 4 matrix metalloproteinase (MT4-MMP) and its different forms in melanoma. Cell Physiol Biochem 2017;42:198-210.
26.
Li X, Hong M, Zhu D, et al: OS 29-05 renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension. J Hypertens 2016;34(suppl 1):e254.
27.
Li JM, Shah AM: Mechanism of endothelial cell NADPH oxidase activation by angiotensin II: role of the p47phox subunit. J Biol Chem 2003;278:12094-12100.
28.
Pueyo ME, Gonzalez W, Nicoletti A, et al: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-651.
29.
Piqueras L, Kubes P, Alvarez A, et al: Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT1 and AT2 receptor-mediated P-selectin upregulation. Circulation 2000;102:2118-2123.
30.
Yi R, Xiao-Ping G, Hui L: Atorvastatin prevents angiotensin II-induced high permeability of human arterial endothelial cell monolayers via ROCK signaling pathway. Biochem Biophys Res Commun 2015;459:94-99.
31.
Maeda R, Noiri E, Isobe H, et al: A water-soluble fullerene vesicle alleviates angiotensin II-induced oxidative stress in human umbilical venous endothelial cells. Hypertens Res 2008;31:141-151.
32.
Hu HJ, Jiang ZS, Qiu J, et al: Protective effects of hydrogen sulfide against angiotensin II-induced endoplasmic reticulum stress in HUVECs. Mol Med Rep 2017;15:2213-2222.
33.
Ahn HY, Kim CH, Ha TS: Epigallocatechin-3-gallate regulates NADPH oxidase expression in human umbilical vein endothelial cells. Korean J Physiol Pharmacol 2010;14:325-329.
34.
Chae YJ, Kim CH, Ha TS, et al: Epigallocatechin-3-O-gallate inhibits the angiotensin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. Cell Physiol Biochem 2007;20:859-866.
35.
Schulz A, Jankowski J, Zidek W, et al: Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS. Clin Proteomics 2014;11:37.
36.
Li M, Liu X, He Y, et al: Celastrol attenuates angiotensin II mediated human umbilical vein endothelial cells damage through activation of Nrf2/ERK1/2/Nox2 signal pathway. Eur J Pharmacol 2017;797:124-133.
37.
Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-1916.
38.
Zhang WJ, Li PX, Guo XH, et al: Role of moesin, Src and ROS in advanced glycation end product-induced vascular endothelial dysfunction. Microcirculation 2017;27:e12358.
39.
Kowald A, Kirkwood TB: Mitochondrial mutations, cellular instability and ageing: modelling the population dynamics of mitochondria. Mutat Res 1993;295:93-103.
40.
Rogers C, Davis B, Neufer PD, et al: A transient increase in lipid peroxidation primes preadipocytes for delayed mitochondrial inner membrane permeabilization and ATP depletion during prolonged exposure to fatty acids. Free Radic Biol Med 2014;67:330-341.
41.
Mateen S, Moin S, Khan AQ, et al: Increased reactive oxygen species formation and oxidative stress in rheumatoid arthritis. PLoS One 2016;11:e0152925.
42.
Zhu Y, Zhang YJ, Liu WW, et al: Salidroside suppresses HUVECs cell injury induced by oxidative stress through activating the Nrf2 signaling pathway. Molecules 2016;21:E1033.
43.
Sedlic F, Muravyeva MY, Sepac A, et al: Targeted modification of mitochondrial ROS production converts high glucose-induced cytotoxicity to cytoprotection: effects on anesthetic preconditioning. J Cell Physiol 2017;232:216-224.
44.
Saha D, Koli S, Reddy KV: Transcriptional regulation of Hb-alpha and Hb-beta through nuclear factor E2-related factor-2 (Nrf2) activation in human vaginal cells: a novel mechanism of cellular adaptability to oxidative stress. Am J Reprod Immunol 2017;77:e12645.
45.
Prasad S, Sajja RK, Kaisar MA, et al: Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity. Redox Biol 2017;12:58-69.
46.
Lv H, Liu Q, Zhou J, et al: Daphnetin-mediated Nrf2 antioxidant signaling pathways ameliorate tert-butyl hydroperoxide (t-BHP)-induced mitochondrial dysfunction and cell death. Free Radic Biol Med 2017;106:38-52.
47.
Duan J, Guan Y, Mu F, et al: Protective effect of butin against ischemia/reperfusion-induced myocardial injury in diabetic mice: involvement of the AMPK/GSK-3β/Nrf2 signaling pathway. Sci Rep 2017;7:41491.
48.
Hyung JH, Ahn CB Il, Kim B, et al: Involvement of Nrf2-mediated heme oxygenase-1 expression in anti-inflammatory action of chitosan oligosaccharides through MAPK activation in murine macrophages. Eur J Pharmacol 2016;793:43-48.
49.
Liu J, Zhang FF, Li L, et al: ClC-3 deficiency prevents apoptosis induced by angiotensin II in endothelial progenitor cells via inhibition of NADPH oxidase. Apoptosis 2013;18:1262-1273.
50.
Evangelista AM, Thompson MD, Bolotina VM, et al: Nox4- and Nox2-dependent oxidant production is required for VEGF-induced SERCA cysteine-674 S-glutathiolation and endothelial cell migration. Free Radic Biol Med 2012;53:2327-2334.
51.
Kim YM, Kim SJ, Tatsunami R, et al: ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria in VEGF signaling and angiogenesis. Am J Physiol Cell Physiol 2017;312:C749-C764.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.